Am J Manag Care. 2006 Dec;12(17 Suppl):S473-83.
Decreasing risk: impact of HPV vaccination on outcomes.
Hymel PA.
Cisco Systems, 170 Tasman Dr, Bldg 5-3, San Jose, CA 95134, USA. phymed@cisco.com
Cervical cancer, caused by oncogenic types of human papillomavirus (HPV),
remains a major health problem worldwide. The recent introduction of a
quadrivalent vaccine (Gardasil), which targets HPV strains responsible for
approximately 70% of cervical cancer cases and 90% of genital warts, has ushered
in new hope of substantially reducing global prevalence of HPV disease. A
further bivalent HPV vaccine (Cervarix) is in the offing. However, many issues
still need to be addressed, including actual vaccine efficacy in preventing
cervical cancer, public acceptance, use of the vaccine in men, vaccine access,
costs, and impact of the vaccine on cervical cancer screening programs. This
review analyzes some of these issues, and emphasizes the need for a coordinated
effort of patients, parents, health professionals, hospitals, and policymakers
to ensure successful implementation of vaccination programs in the United
States.
  
Please click on the required question. |
